<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04943718</url>
  </required_header>
  <id_info>
    <org_study_id>2019-127</org_study_id>
    <nct_id>NCT04943718</nct_id>
  </id_info>
  <brief_title>Personalized Vaccine for Patients With Recurrent Malignant Glioma</brief_title>
  <official_title>Personalized Vaccine for Patients With Recurrent Malignant Glioma: a Single-arm, Single-center, Open-labeled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Neoantigen Biotechnology Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xuanwu Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single-arm, single-center, open-labeled study will be conducted with an aim to investigate&#xD;
      the feasibility, safety, and efficacy of the personalized vaccine for patients with recurrent&#xD;
      malignant glioma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 15, 2021</start_date>
  <completion_date type="Anticipated">June 13, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 13, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidences of advent events and severe advent events</measure>
    <time_frame>from initiation of study treatment to 28 weeks post-vaccination</time_frame>
    <description>would be monitored and measured according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.X.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>object response rate (ORR) according to iRANO criteria</measure>
    <time_frame>from initiation of study treatment to 24 weeks post-vaccination (last shot)</time_frame>
    <description>ORR including complete response (CR) and partial response (PR) would be assessed and measured based on the conditions proposed by iRANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival (PFS)</measure>
    <time_frame>up to 48 weeks post-vaccination(last shot)</time_frame>
    <description>time interval (measured in weeks) between initiation of study treatment to progression of disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>up to 48 weeks post-vaccination(last shot)</time_frame>
    <description>time interval (measured in weeks) from initiation of study treatment to the death of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immune response based on the criteria encoded by GRT-C903 and GRT-R904</measure>
    <time_frame>Baseline to end of treatment (up to approximately 12 months)</time_frame>
    <description>humoral and cellular immune responses including generation of specific antibodies, inflammatory factors, immune cells, will be measured as proposed by GRT-C903 and GRT-R904</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Malignant Glioma</condition>
  <condition>Recurrent Glioma</condition>
  <arm_group>
    <arm_group_label>personalized vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with recurrent malignant gliomas enrolled into this arm will receive the personalized vaccine through sub-cutaneous.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>personalized vaccine</intervention_name>
    <description>Based on genetic and transcriptional sequencing information, personalized peptide vaccines would be designed and produced; patients would be vaccinated on day 1, 4, 8 ,15, 22 and then on week 12, 20.</description>
    <arm_group_label>personalized vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 18-70;&#xD;
&#xD;
          -  signed inform consent;&#xD;
&#xD;
          -  patients with recurrent malignant glioma; have received surgery, radiotherapy,&#xD;
             chemotherapy;&#xD;
&#xD;
          -  patients' tumor tissue should have a high mutation load(&gt;10 TMB); be genetically&#xD;
             unstable; at least have 10 neoantigens;&#xD;
&#xD;
          -  should be able to provide tumor tissue and peripheral blood for sequencing and flow&#xD;
             cytometry analysis;&#xD;
&#xD;
          -  at least three months post last operation; one month after the completion of the last&#xD;
             anti-drug therapy or radiotherapy;&#xD;
&#xD;
          -  have not received any immune therapy;&#xD;
&#xD;
          -  at least have one measurable lesion;&#xD;
&#xD;
          -  KPS &gt;60;&#xD;
&#xD;
          -  estimated survival &gt; 3 months&#xD;
&#xD;
          -  patients should have adequate organ and bone marrow function;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  female patient is breastfeeding or pregnant;&#xD;
&#xD;
          -  known history of allergy to peptides or other stimulating factors (i.e. GM-CSF);&#xD;
&#xD;
          -  known history of Graft-Versus-Host Disease (GVHD);&#xD;
&#xD;
          -  participation in gene therapy;&#xD;
&#xD;
          -  other malignancy;&#xD;
&#xD;
          -  systemic disease: i.e., severe infection; HIV;&#xD;
&#xD;
          -  other conditions upon investigator's judgement;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qingtang Lin, M.D., Ph.D.</last_name>
    <phone>8610-83198114</phone>
    <phone_ext>2683</phone_ext>
    <email>linqingtang@xwhosp.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xuanwu Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100054</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ye Cheng, M.D.</last_name>
      <phone>8610-83188114</phone>
      <phone_ext>2683</phone_ext>
      <email>chengye@xwhosp.org</email>
    </contact>
    <investigator>
      <last_name>Qingtang Lin, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ye Cheng, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 13, 2021</study_first_submitted>
  <study_first_submitted_qc>June 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>June 26, 2021</last_update_submitted>
  <last_update_submitted_qc>June 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xuanwu Hospital, Beijing</investigator_affiliation>
    <investigator_full_name>Qingtang Lin</investigator_full_name>
    <investigator_title>Director, glioma immunotherapy program</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

